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Abstract. 
 
Many factors influence the assembly of fi-
bronectin into an insoluble fibrillar extracellular ma-
trix. Previous work demonstrated that one component 
in serum that promotes the assembly of fibronectin is 
lysophosphatidic acid (Zhang, Q., W.J. Checovich, 
 
D.M. Peters, R.M. Albrecht, and D.F. Mosher. 1994. 
 
J. 
Cell Biol.
 
 127:1447–1459). Here we show that C3 trans-
ferase, an inhibitor of the low molecular weight GTP-
binding protein Rho, blocks the binding of fibronectin 
 
and the 70-kD NH
 
2
 
-terminal fibronectin fragment to 
cells and blocks the assembly of fibronectin into matrix 
induced by serum or lysophosphatidic acid. Microinjec-
tion of recombinant, constitutively active Rho into qui-
escent Swiss 3T3 cells promotes fibronectin matrix as-
sembly by the injected cells. Investigating the 
mechanism by which Rho promotes fibronectin poly-
merization, we have used C3 to determine whether in-
tegrin activation is involved. Under conditions where 
C3 decreases fibronectin assembly we have only de-
tected small changes in the state of integrin activation. 
However, several inhibitors of cellular contractility, 
that differ in their mode of action, inhibit cell binding of 
fibronectin and the 70-kD NH
 
2
 
-terminal fibronectin 
fragment, decrease fibronectin incorporation into the 
deoxycholate insoluble matrix, and prevent fibronec-
tin’s assembly into fibrils on the cell surface. Because 
Rho stimulates contractility, these results suggest that 
Rho-mediated contractility promotes assembly of fi-
bronectin into a fibrillar matrix. One mechanism by 
which contractility could enhance fibronectin assembly 
is by tension exposing cryptic self-assembly sites within 
fibronectin that is being stretched. Exploring this possi-
bility, we have found a monoclonal antibody, L8, that 
stains fibronectin matrices differentially depending on 
the state of cell contractility. L8 was previously shown 
to inhibit fibronectin matrix assembly (Chernousov, 
M.A., A.I. Faerman, M.G. Frid, O.Y. Printseva, and 
V.E. Koteliansky. 1987. 
 
FEBS (Fed. Eur. Biochem. 
Soc.) Lett. 
 
217:124–128). When it is used to stain nor-
mal cultures that are developing tension, it reveals a 
matrix indistinguishable from that revealed by poly-
clonal anti-fibronectin antibodies. However, the stain-
ing of fibronectin matrices by L8 is reduced relative to 
the polyclonal antibody when the contractility of cells is 
inhibited by C3. We have investigated the conse-
quences of mechanically stretching fibronectin in the 
absence of cells. Applying a 30–35% stretch to immobi-
lized fibronectin induced binding of soluble fibronectin, 
70-kD fibronectin fragment, and L8 monoclonal anti-
body. Together, these results provide evidence that 
self-assembly sites within fibronectin are exposed by 
tension. 
 
F
 
ibronectin
 
 (FN)
 
1
 
 is a large, multi-module extracel-
lular matrix (ECM) protein that exists in two major
states, either circulating in plasma as a soluble
dimeric protein or found within ECMs as an insoluble
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component associated with cells and other ECM compo-
nents. The structure of FN and its many functions have
been reviewed (31, 48). FN plays a major role in cell adhe-
sion, migration, differentiation, and growth regulation. FN
has been implicated in normal wound healing and in em-
bryonic development. Disruption of the FN gene in mice
results in an embryonic lethal phenotype, confirming the
importance of FN in development (23). Loss of FN from
 
glutathione-S-transferase; H7, 1-(5-isoquinolinylsulfonyl)-2-methylpiper-
azine; LPA, lysophosphatidic acid; ML-7, 1-(5-chloronaphthalenesulfo-
nyl)-1H-hexahydro-1,4-diazepine; R-MCF10A, Ras-transformed MCF10A
breast epithelial cells.
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the cell surface is a characteristic of many transformed and
tumorigenic cells. Restoration of a FN matrix often sup-
presses the transformed phenotype (24, 31). Many of the
effects of FN on cells are exerted by FN when it is in the
form of a fibrillar matrix. Although much has been learned
about the assembly of FN into a matrix, this process is not
fully understood (for reviews see references 49 and 51).
One factor that affects the assembly of the FN matrix is
the state of the actin cytoskeleton. It has long been known
that disruption of actin filaments with cytochalasin inhibits
matrix assembly (2, 13, 67). Newly assembled FN fibrils
coalign with bundles of actin filaments (27, 32), and with
focal adhesions or cytoskeletal structures that contain
many focal adhesion proteins (3, 7, 8, 10, 61). In addition,
fluorescent fragments of FN involved in matrix assembly
target to focal adhesions when added to cells (13, 18, 29,
63). The reason why an intact cytoskeleton is necessary for
matrix assembly has not been established.
Another factor well known to promote FN matrix as-
sembly is serum (40, 50). In serum a potent component
promoting FN assembly was identified as lysophosphatidic
acid (LPA) (9, 71). LPA is a bioactive lipid that triggers
several signaling pathways, including mobilization of intra-
cellular calcium, activation of phospholipase C, activation
of protein kinase C, and activation of the GTP-binding
protein, Rho (43). Rho itself triggers multiple signaling
pathways (56). A prominent pathway stimulates assembly
of large bundles of actin filaments (stress fibers) and focal
adhesions (57). This effect on stress fiber and focal adhe-
sion formation is due to Rho-stimulating contractility (15),
which occurs via a kinase/phosphatase cascade that ele-
vates myosin light chain phosphorylation (6, 35). Light
chain phosphorylation stimulates myosin ATPase activity
and myosin filament formation (6). 
Here we have investigated whether the effect of LPA on
FN matrix assembly is mediated via Rho, and in particular,
by Rho-stimulated contractility. Inhibiting Rho blocks FN
matrix assembly, whereas introducing recombinant, con-
stitutively active Rho into quiescent Swiss 3T3 cells pro-
motes matrix assembly by these cells. Inhibitors of cellular
contractility antagonize the effect of LPA on matrix as-
sembly, indicating that Rho-generated tension has a criti-
cal role in the assembly of the FN matrix. While this work
was under review, similar results indicating that LPA stim-
ulates FN matrix assembly via Rho and contractility were
published (70). It was suggested by the authors of that
study that contractility may stretch the uncharacterized
molecules of large apparent molecular mass that they have
suggested serve as FN assembly sites, thereby exposing
cryptic binding sites for FN. However, previous work has
identified cryptic self-association sites within FN (28, 29,
33) and it has also been proposed that these may be ex-
posed by tension (28, 29, 67). Consistent with this idea, we
have identified an mAb, previously shown to block assem-
bly, that demonstrates enhanced binding to FN matrices
when cells are contractile. In addition, we have detected
increased binding of this antibody to FN that has been me-
chanically stretched in the absence of cells. Similarly, com-
pared with unstretched FN, stretched FN binds more ex-
ogenous FN and more of the NH
 
2
 
-terminal, 70-kD FN
fragment. These observations support the idea that ten-
sion generated by cells exposes self-assembly sites within
FN. A model for how tension may promote the incorpora-
tion of FN molecules into a fibrillar matrix is proposed.
 
Materials and Methods
 
Cell Culture 
 
Swiss 3T3 fibroblasts (American Type Culture Collection, Rockville,
MD), were grown in DME (Life Technologies, Inc., Gaithersburg, MD),
with 100 units/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 250 ng/ml am-
photericin B as fungizone, supplemented with 10% bovine calf serum
(BCS) (JRH Biosciences, Lenexa, KS). Quiescence was obtained as de-
scribed before (14). Briefly, in each experiment cells were seeded at iden-
tical density in 100-mm tissue culture dishes and maintained in the culture
medium with serum, without feeding. The cells were used 7–10 d after
they reached confluence, at which time they were washed and starved in
serum-free culture medium for 16–24 h. Quiescent, serum-starved cells
were stimulated with culture medium containing 0.5% FBS (JRH Bio-
sciences) or 2 
 
m
 
g/ml LPA (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate,
monosodium salt in H
 
2
 
O) (Avanti Polar Lipids, Alabaster, AL) for the in-
dicated periods of time. A time course of the response to LPA treatment
revealed maximal stress fiber induction at 2–4 h and FN matrix assembly
at 4–6 h as judged by immunofluorescence microscopy. To maintain a
maximal stimulation in experiments measuring incorporation of FN into
the detergent-insoluble matrix, we replenished LPA at 4–5-h intervals.
Ras-transformed human breast epithelial cells (R-MCF10A) (36) were
grown in DME and Ham’s F12 medium (1:1 ratio) containing 5% horse
serum, 20 ng/ml EGF, 10 
 
m
 
g/ml insulin, and 0.5 
 
m
 
g/ml hydrocortisone.
In some experiments an inhibitor of actin–myosin interactions, 2,3-
butanedione 2-monoxime (BDM; Sigma Chemical Co., St. Louis, MO)
was used at a final concentration of 2.5–20 mM. Because of BDM’s insta-
bility in aqueous solutions (16), for long-term experiments measuring the
effect of BDM on the assembly of FN into the detergent-insoluble matrix,
we added BDM in four aliquots of 5 mM each, 30 min before the addition
of LPA at each 5-h interval. Another inhibitor of contractility, 1-(5-iso-
quinolinylsulfonyl)-2-methylpiperazine (H7; Sigma Chemical Co.) was
added at 150–300 
 
m
 
M final concentration. 1-(5-chloronaphthalenesulfo-
nyl)-1H-hexahydro-1,4-diazepine, (ML-7; BIOMOL, Plymouth Meeting,
PA) was used at a final concentration of 2.5–25 
 
m
 
M. 
 
Immunofluorescence Microscopy
 
Immunofluorescence was performed as described previously (15). Actin
was stained with FITC–phalloidin (Molecular Probes, Inc., Eugene, OR).
In some experiments FN was stained with a polyclonal rabbit anti–human
FN antibody provided by Dr. L.B. Chen (Dana-Farber Cancer Center,
Boston, MA), or with an mAb (Transduction Labs, Lexington, Kentucky)
followed by TRITC-labeled donkey anti–rabbit or donkey anti–mouse
IgG (Chemicon International, Inc., Temecula, CA). The L8 and C6F10
mAbs were provided by Dr. M. Chernousov (Weiss Center for Research,
Danville, PA) and have been characterized previously (11, 12, 17). L8
binds to an epitope in I
 
9
 
III
 
1
 
 FN domains. C6F10 binds to the FN III
 
10
 
module close to the RGDS sequence. For double immunofluorescence,
L8 and C6F10 were used at 50 
 
m
 
g/ml in combination with the polyclonal
anti-FN. Cells microinjected with recombinant Rho were comicroinjected
with a marker IgG (FITC-conjugated goat anti–human IgG fraction; Cap-
pel, Organon-Technika, Durham, NC). 
 
Purification and Microinjection of
Recombinant Proteins
 
Recombinant Val14rhoA (a gift from Dr. A. Hall, University College,
London, UK) and recombinant C3 transferase (a gift from Dr. L. Feig,
Tufts University, Boston, MA) were expressed as a glutathione-S-trans-
ferase (GST) fusion protein in 
 
Escherichia coli
 
. Proteins were purified on
glutathione–agarose beads as described before (34, 57) and cleaved from
GST with thrombin (Sigma Chemical Co.) in a buffer (50 mM TrisCl, pH
7.5, 50 mM NaCl, 5 mM MgCl
 
2
 
, 1 mM DTT, 1 mM PMSF; C3: 50 mM
TrisCl, pH 8.0, 150 mM NaCl, 2.5 mM CaCl
 
2
 
, 5 mM DTT), which was then
removed by three subsequent incubations with 
 
para
 
-aminobenzamidine
agarose (Sigma Chemical Co.). Rho was dialyzed against microinjection
buffer (50 mM TrisCl, pH 7.5, 50 mM KCl, 5 mM MgCl
 
2
 
, 0.1 mM DTT)
and concentrated to 2–3 mg/ml using a Centricon concentrator (Amicon
Inc., Beverly, MA). Purified Rho was loaded by capillarity into needles 
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pulled on a Brown-Flaming micropipette puller (Sutter Instrument Co.,
San Francisco, CA) and injected into cells as described previously (8).
Cells were injected for 15–30 min and then incubated at 37
 
8
 
C in an atmo-
sphere of 10% CO
 
2
 
 for 4–5 h in the presence of 100 
 
m
 
g/ml human plasma
FN (GIBCO BRL, Gaithersburg, MD or Chemicon International, Inc., or
purified as described in reference 31). 
C3 was concentrated using a Centricon concentrator and, for Swiss 3T3
cells, was added to the culture media at 25 
 
m
 
g/ml during 16–24-h starva-
tion and at the same concentration following stimulation of cells with
LPA. To introduce C3 transferase into R-MCF10A cells, cells were incu-
bated with the same concentration of C3 in serum-containing media for 48 h.
 
Fibronectin and 70-kD Fibronectin Fragment Binding
 
The 70-kD FN fragment was purified as previously described (42). FN and
the 70-kD FN fragment were labeled with 
 
125
 
I, using the Iodogen method
(21). The specific activities were 2.5–4 
 
3 
 
10
 
6
 
 cpm/
 
m
 
g for FN and 3.8 
 
3 
 
10
 
6
 
–
1.9 
 
3
 
 10
 
7
 
 cpm/
 
m
 
g for the 70-kD FN fragment. To measure the initial bind-
ing of FN and 70-kD FN fragment to cells, Swiss 3T3 or R-MCF10A cells
were plated in 24-well plates. For Swiss 3T3 cells, after they had reached
confluence, they were maintained for several days before being starved
for 24 h and in some cases being incubated with C3 for the same period of
time. Some starved cells were pretreated for 1 h with contractility inhibi-
tors (either 20 mM BDM or 300 
 
m
 
M H7) and kept in the presence of con-
tractility inhibitors during the incubation with 
 
125
 
I-FN or 
 
125
 
I-labeled 70-
kD FN fragment. Cultures were then stimulated with 2 
 
m
 
g/ml LPA for 30
min, followed by the addition of the 
 
125
 
I-FN or 
 
125
 
I-labeled 70-kD FN
fragment. Cells were incubated with 
 
125
 
I-FN (300 ng; 7.5 
 
3
 
 10
 
5
 
 cpm/well)
or 
 
125
 
I-labeled 70-kD FN fragment (300 ng; 1.1 
 
3 
 
10
 
6
 
 cpm/well) in DME
containing 2 mg/ml of delipidated BSA for 2 h at 37
 
8
 
C. For time course ex-
periments, 
 
125
 
I-FN was incubated with either serum-starved or LPA-stim-
ulated cells for the indicated periods of time. Nonspecific binding was de-
termined by coincubation the cells with 400 
 
m
 
g/ml of unlabeled FN or 100
 
m
 
g/ml of unlabeled 70-kD FN fragment. For recovery experiments,
starved cells treated with either BDM or H7 for 1 h, were allowed to re-
cover in regular growth medium for 2 h before addition of 
 
125
 
I-FN for 30
min. After incubations, the cells were washed three times with DME, cell
layers were lysed in 1 N NaOH, and radioactivity was measured in a
gamma counter. Duplicate measurements were performed for each exper-
imental condition. For R-MCF10A cells, cells were pretreated with con-
tractility inhibitors for 2 h before adding 
 
125
 
I-labeled 70-kD FN fragment.
To measure the incorporation of FN into the cross-linked matrix, Swiss
3T3 cells were plated in six-well dishes at identical density in 10% bovine
calf serum in DME, grown to confluency, washed, and then starved as de-
scribed above. Confluent R-MCF10A cells were transferred to the me-
dium containing 0.5% horse serum before adding 
 
125
 
I-FN. For Swiss 3T3
cells, 
 
125
 
I-FN (18 
 
m
 
g/ml; 4.5 
 
3
 
 10
 
7
 
 cpm/dish) was added and the cells were
stimulated with LPA in the presence or absence of inhibitors, as described
above. The medium was then removed and cells were washed three times
in PBS. The deoxycholate (DOC)-insoluble fraction (cross-linked FN) was
harvested as described before (42). Briefly, the dishes were washed for 1
min with 1 ml each of ice-cold buffer A (3% Triton X-100 in PBS, 10 mM
EDTA, 1 mM PMSF, 1 mM benzamidine, 10 
 
m
 
g/ml aprotinin, and 10 
 
m
 
g/ml
leupeptin), buffer B (50 mM Tris-HCl, pH 7.4, 1 M NaCl, 10 mM MnCl
 
2
 
,
100 
 
m
 
g/ml DNase I, 1 mM benzamidine, 10 
 
m
 
g/ml aprotinin, and 10 
 
m
 
g/ml
leupeptin), and buffer C (2% sodium deoxycholate in 50 mM Tris-HCl,
pH 8.8, 10 mM EDTA, 1 mM benzamidine, 10 
 
m
 
g/ml aprotinin, and 10 
 
m
 
g/ml
leupeptin). The DOC-insoluble fraction was then rinsed with PBS and
scraped into SDS sample buffer and boiled. 
 
125
 
I-FN incorporation by cells
under different experimental conditions was measured using a gamma
counter. Aliquots of the DOC-insoluble fraction were run on a 7.5% SDS-
PAGE gel. Gels were dried and processed for autoradiography to visual-
ize FN bands. Each assay was performed in duplicate. Similar procedures
were used to measure the incorporation of FN into cross-linked matrix on
the surface of R-MCF10A cells in the presence or absence of contractility
inhibitors.
 
Silicone Rubber Substrates
 
To visualize cell contractility, flexible rubber substrates have been gener-
ated as previously described (15).
 
Integrin Activation Assays
 
The level of 
 
b
 
1 integrin activation was measured using the antibody
12G10 (Serotec Ltd., Kidlington, Oxford, UK). This antibody binds to a
 
ligand-induced epitope on human 
 
b
 
1 integrins (52, 53). Parallel wells of
cells under various conditions were incubated with 0.5 
 
m
 
g/ml 
 
125
 
I-12G10
(specific activity: 1.75 
 
3
 
 10
 
5
 
 cpm/
 
m
 
g) or with 
 
125
 
I-TS2/16 (specific activity:
3.8 
 
3
 
 10
 
5
 
 cpm/
 
m
 
g) for 1 h at 37
 
8
 
C. To induce a high affinity state of the in-
tegrin, cells were incubated with 100 
 
m
 
M MnCl
 
2
 
 (22) during the incuba-
tion with primary antibody. Nonspecific binding was determined by com-
petition of binding with an excess of unlabeled antibody and this was
substracted from the values obtained under the different experimental
conditions. Cell number was equalized by TS2/16 binding and the percent-
age of integrin activation calculated by 
 
g
 
0
 
/
 
g
 
 
 
3 
 
100, where 
 
g
 
0
 
 was the cpm
without Mn
 
2
 
1
 
 and 
 
g
 
 was the cpm obtained in the presence of 100 
 
m
 
M
Mn
 
2
 
1
 
.
 
Binding of 
 
125
 
I-Labeled mAbs L8 and C6F10 to FN 
Matrices Assembled by Cultured Cells
 
Purified mAbs L8 and C6F10 were labeled with 
 
125
 
I using the Iodogen
method (21). The specific activities of both antibodies were 2.5 
 
3 
 
10
 
6
 
 cpm/
 
m
 
g.
To measure the binding of mAbs to FN matrices in culture, Swiss 3T3 cells
were grown to 50–80% confluence in 24-well plates in the presence of 80
 
m
 
g/ml human plasma FN. Cells were changed to serum-free medium, with
or without C3 transferase at 25 
 
m
 
g/ml for 24 h. Under these conditions, the
cells in the absence of C3 continued to display normal stress fibers,
whereas those with C3 had lost them (data not shown). Cells growing in
the presence or absence of C3 were washed three times with serum-free
medium and then incubated for 1 h at 37
 
8
 
C with 3 
 
m
 
g of 
 
125
 
I-labeled L8 or
C6F10 in DME containing 2 mg/ml delipidated BSA. Nonspecific binding
was determined in the presence of excess unlabeled mAbs. After the incu-
bations, the cultures were washed three times with DME, and then dis-
solved in 1 N NaOH. Bound radioactivity was measured in a gamma
counter. The ratio of the amount of bound L8 to that of bound C6F10 was
determined for both untreated and C3-treated cells.
 
Mechanical Stretching of FN
 
To apply tension to FN in the absence of cells, purified FN (10 
 
m
 
g/ml) was
covalently coupled to chemically activated, flexible rubber “Bioflex” cul-
ture dishes (FlexCell International Corp., McKeesport, PA) (provided by
Dr. A. Banes, University of North Carolina, Chapel Hill, NC). Three adja-
cent circles were marked in the centers of each well using the top of a cell
cryotube (Nunc Inc., Naperville, IL) coated with silicon vacuum grease.
All coupling reactions and binding experiments were performed within
these restricted areas. Coupling of FN to the rubber was performed in
PBS for 1 h at room temperature. Reactive groups were blocked with 100
mM ethanolamine, pH 7.5, for 40 min at room temperature. The amount
of FN coupled to the surface was calculated by including a fraction of 
 
125
 
I-
FN in the coupling reaction. Before addition of ligands, sites for nonspe-
cific adsorption of proteins were blocked by preincubation of the rubber
both before and after stretching with 2 mg/ml BSA in Tris-buffered saline
(150 mM NaCl, 50 mM TrisHCl, pH 7.6, 0.1% NaN
 
3
 
) for 45 min. A sus-
tained stretch of the FN-coated rubber was achieved by placing the cul-
ture dishes over vaseline-coated, plastic soda bottle lids and applying a
large uniform weight on top of the dishes. This caused the rubber surfaces
to be stretched over the bottle lids. The vaseline coating minimized the
friction between the lid and the rubber, resulting in a uniform stretch of
the rubber over the top of the lid. This procedure resulted in a linear
stretch of between 30 and 35%. For binding experiments, stretched and
unstretched wells were incubated for 1 h at room temperature with 30 
 
m
 
l
of TBS containing 2 mg/ml BSA and 5 
 
3 
 
10
 
5
 
 cpm 
 
125
 
I-FN (4 
 
3
 
 10
 
6
 
 cpm/
 
m
 
g),
5 
 
3
 
 10
 
5
 
 cpm 
 
125
 
I-labeled 70-kD fragment of FN (1.9 
 
3
 
 10
 
7
 
 cpm/
 
m
 
g), and
10
 
6
 
 cpm 
 
125
 
I-L8 (6 
 
3
 
 10
 
7
 
 cpm/
 
m
 
g) or 
 
125
 
I-C6F10 (10
 
7
 
 cpm/
 
m
 
g). After bind-
ing, the surfaces were washed multiple times with excess of TBS. For the
FN-binding experiments, one wash occurred overnight. In each case, val-
ues for nonspecific binding to stretched and unstretched surfaces were cal-
culated and deducted by measuring the binding in the presence of excess
of unlabeled reagent (1 mg/ml for FN and 70-kD FN fragment, 0.5 mg/ml
for the labeled antibodies).
 
Results
 
Rho Is Involved in the Stimulation of FN Matrix 
Assembly by Serum or LPA
 
Previous work has demonstrated that serum and LPA 
The Journal of Cell Biology, Volume 141, 1998 542
 
stimulate FN assembly (71). Swiss 3T3 cells are a cell type
well suited to examining whether the effects of serum and
LPA are mediated via the GTP-binding protein, Rho. In
the absence of serum, these cells become quiescent, lose
stress fibers, and focal adhesions, but can be stimulated by
serum or LPA to reassemble these structures in a Rho-
dependent mechanism (57). We have examined FN matrix
assembly by these cells, under conditions of quiescence or
in response to stimulation by serum or LPA (Fig. 1). For
most of these experiments, we have added exogenous FN
because Swiss 3T3 cells only synthesize low levels of FN.
When the cells are rendered quiescent by overnight serum
deprivation, few stress fibers (Fig. 1 A) and little FN ma-
trix (Fig. 1 B) are detected. In the presence of serum, the
cells reveal prominent stress fibers (Fig. 1 C) and a fibrillar
FN matrix (Fig. 1 D). Stimulation of quiescent cells with
LPA similarly promoted organized stress fibers (Fig. 2 A)
and FN matrix (Fig. 2 B).
To determine whether the assembly of FN matrix in
response to serum or LPA was dependent on Rho, we
have used the Rho inhibitor C3 transferase. C3 is taken
up by some cells slowly over time, so that its addition to
the medium is sufficient to inhibit Rho activity (68). Qui-
escent Swiss 3T3 cells were pretreated with C3 before and
during addition of serum and FN (Fig. 1, E and F). The C3
treatment abolished assembly of stress fibers (Fig. 1 E)
and the formation of a FN matrix (Fig. 1 F). Similarly, C3
treatment blocked stress fiber and FN assembly in re-
sponse to LPA stimulation of quiescent Swiss 3T3 cells
(Fig. 2, C and D).
Activated Rho Stimulates FN Matrix Assembly 
The inhibition of FN matrix assembly by C3 transferase
provides strong evidence that Rho is involved in this pro-
cess. To obtain further evidence for the involvement of
Rho, we used microinjection to introduce recombinant,
constitutively active Rho into quiescent Swiss 3T3 cells
cultured in the presence of exogenous FN. Microinjection
of active Rho stimulated matrix assembly by the injected
cells (Fig. 3, A and B). In contrast, injection of only the
marker protein used to identify the injected cells did not
stimulate matrix assembly over the level that was detected
in noninjected cells (Fig. 3, C and D).
Inhibitors of Contractility Block the Assembly of FN 
Matrix Induced by LPA
Previous work has shown that Rho-mediated assembly of
stress fibers and focal adhesions involves increased con-
tractility and can be blocked by inhibitors of actin–myosin
activation or force generation (15). We have explored the
effects of inhibitors of contractility on matrix assembly in-
duced by LPA. Both BDM and H7 have been used previ-
ously to inhibit cell contraction (15, 65). These agents
caused a complete block to stress fiber assembly (Fig. 2, E
and G) and FN matrix assembly (Fig. 2, F and H), consis-
tent with contractility contributing to both events.
For reasons described below, a second cell type had to
be used to determine whether inhibiting Rho affected the
activation state of integrins. It was important, therefore, to
first explore the effects of inhibiting Rho and contractility
on the deposition of a FN matrix by these cells. R-MCF10A
cells, although transformed, exhibit many of the character-
istics of a normal fibroblastic phenotype, including promi-
nent stress fibers and focal adhesions (36). Furthermore,
we have recently shown that inhibiting Rho in these cells
leads to disassembly of stress fibers and focal adhesions
Figure 1. Serum induces fibronectin assembly in
a Rho-dependent manner. Exogenous FN was
added to quiescent, serum-starved Swiss 3T3 fi-
broblasts for 24 h (A and B), or to cells that were
stimulated with serum for 24 h in the absence (C
and D) or presence of C3 transferase (E and F).
Cells were stained for actin (A, C, and E) and FN
(B, D, and F). Quiescent cells have poorly devel-
oped actin stress fibers (A), and there is little FN
assembly (B). Stimulation with serum induces
stress fibers (C) and FN fibril assembly (D).
These effects of serum are blocked when cells
are incubated with C3 (E and F). Bar, 20 mm.Zhong et al. Rho, Contractility and Fibronectin Matrix Assembly 543
(72). R-MCF10A cells develop an extensive FN matrix
when grown routinely in the presence of serum (Fig. 4 A).
The assembly of a FN matrix was inhibited by the myosin
light chain kinase inhibitor ML-7 (Fig. 4 B) and by BDM
(Fig. 4 C). Both of these inhibitors were found to decrease
the contractility of these cells as judged by their ability to
wrinkle a flexible rubber substratum upon which they
were growing (72). We also examined the effect of inacti-
vating Rho in these cells. Treatment of R-MCF10A cells
with C3 abolished FN matrix assembly (Fig. 4 D) and this
effect correlated with a decrease in contractility indicated
by decreased wrinkling of rubber substrata (Fig. 4, E and F).
Quantitation of FN and 70-kD FN Fragment Binding to 
Cells and Incorporation into Matrix
We have performed several types of experiment to mea-
sure the effects of Rho activation and cell contractility on
the binding of FN and its 70-kD fragment to cells. A time
course analysis of the effects of LPA on FN binding to
cells showed that stimulation was detectable as early as 15
min and was maximal at 2 h after treatment (Fig. 5 A). We
also examined the initial binding of 125I-labeled FN and
70-kD FN fragment to quiescent Swiss 3T3 cells stimu-
lated with LPA, in the presence or absence of C3 and vari-
ous inhibitors of contractility (Fig. 5 B). Binding of the
125I-FN to confluent LPA-stimulated Swiss 3T3 cells was
significantly decreased by C3, BDM, and H7 (Fig. 5 B).
Numerous studies have demonstrated that the 70-kD
NH2-terminal fragment of FN is responsible for binding of
FN to cells (42). Therefore, we examined the effects of
these contractility inhibitors on the binding of the 125I-labeled
70-kD FN fragment to Swiss 3T3 cells. Binding of the 70-kD
fragment to quiescent cells was stimulated by LPA, and
this stimulation was inhibited by C3, H7 and BDM (Fig. 5
B). To determine whether the effects of the contractility
inhibitors were reversible and not because of cell toxicity,
the medium containing BDM or H7 was replaced with
normal medium containing serum. This led to restoration
of FN binding within 2 h (Fig. 5 C). The reversibility of the
Figure 2. LPA-induced fibronectin assembly is
blocked by inhibitors of Rho and contractility.
Quiescent cells stimulated with LPA for 24 h
form stress fibers (A) and assemble exogenous
FN into matrix (B). Pretreatment of cells with C3
before and during LPA stimulation blocks both
these effects (C and D). Addition of BDM (E
and F) or H7 (G and H) during LPA stimulation
blocks the formation of stress fibers (E and G)
and FN matrix (F and H). Cells were stained for
actin (A, C, E, and G) and FN (B, D, F, and H).
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effect of these agents upon their removal indicated that
they were not adversely affecting the cells and thus bind-
ing of FN in some permanent way.
After the initial binding to cells, FN is incorporated into
growing fibrils and becomes progressively more insoluble.
This is because of disulfide bond formation and finally
other covalent cross-linking events (49). To explore the ef-
fects of Rho-stimulation by LPA, Rho inhibition or inhibi-
tion of contractility on the incorporation of FN into the in-
soluble matrix, binding experiments were performed on
Swiss 3T3 cells over a much longer time course. The incor-
poration of 125I-labeled FN into the DOC-insoluble matrix
of Swiss 3T3 cells was stimulated by LPA and was signifi-
cantly inhibited by C3, BDM, and H7 (Fig. 5 B).
Binding experiments were also performed using the
R-MCF10A cells. Inhibitors of contractility, such as BDM
and ML-7, decreased the binding of the 70-kD FN frag-
ment to cells as compared with the binding to untreated
cells (Fig. 6). Similarly, the incorporation of 125I-FN into
DOC-insoluble matrix by R-MCF10A cells was also di-
minished by BDM and ML-7 (Fig. 6).
Integrin Activation and Matrix Assembly
Many factors contribute to the assembly of a FN matrix.
Several studies have demonstrated the importance of the
integrin a5b1, the major FN receptor, in the assembly of
FN matrix (20, 41, 54). Integrins can exist in low affinity or
high affinity (activated) states with respect to binding to
extracellular ligands (58). Wu and coworkers demon-
strated that integrin activation was necessary for FN ma-
trix assembly (67). Several studies have implicated Rho in
the regulation of integrin activation and so we wished to
determine whether the Rho-dependent assembly of FN
matrix that we were observing was due to integrin activa-
tion. Most frequently integrin activation is measured by
specific mAbs that bind to epitopes that are only exposed
in activated forms of the integrin. No such mAbs are avail-
able for use with mouse cells such as Swiss 3T3 fibroblasts.
The mAb 12G10 has been used to quantitate the activation
state of b1 integrins in human cells (52, 53). The R-MCF10A
cells afforded us the opportunity to determine whether
conditions that inhibit FN matrix assembly coordinately
decrease integrin activation.
We wanted to determine whether the inhibitors of con-
tractility used above might act by affecting the activation
state of a5b1. We examined the binding of 12G10 to cells
treated with or without these inhibitors. Except for a slight
decrease in integrin activation following treatment of cells
with C3, none of the inhibitors tested exhibited any effect
Figure 3. Recombinant, constitutively active
Rho induces fibronectin assembly. Quiescent
cells were microinjected with purified, recombi-
nant active Rho (GST-Val14rho) and marker
IgG (A and B) or with marker IgG alone (C and
D) and exposed to exogenous FN for 5 h. FN (A
and C) is assembled into fibrils only by cells in-
jected with Rho (A), but not with IgG alone (C).
A and C show the organization of FN, B and D
show the injected cells. Bar, 20 mm.
Figure 4. Effects of inhibitors of contractility on fibronectin ma-
trix assembly by R-MCF10A cells. Immunofluorescence micro-
graphs of R-MCF10A cells stained for FN after overnight treat-
ment with serum alone (A) or with serum plus 2.5 mM ML-7 (B),
2.4 mM BDM (C), or for 2 d in culture medium plus 25 mg/ml C3
(D). FN matrix was visualized by staining with an antibody to FN.
In E and F, phase micrographs are shown of the cells cultured on
silicone rubber substrata in the absence (E) or presence (F) of
C3. Bar: (A–D) 20 mm; (E and F) 200 mm. 
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on the state of integrin activation in these cells (Fig. 7).
The C3 effect was small and only of marginal statistical
significance (
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0.025). As a positive control, the cells
were exposed to Mn
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, which has been shown to stimulate
the activated state of integrins (22). Treatment of the
R-MCF10A cells with Mn
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 caused a marked shift in the
amount of 12G10 bound by these cells (Fig. 7) confirming
that a change in activation state of the 
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1 in these cells
could be detected.
 
Cell Tension Exposes a Cryptic Epitope in FN
 
One possible explanation for the observation that cell con-
tractility promotes FN matrix assembly is that tension on
FN molecules stretches particular domains (17) to expose
new binding sites (see Discussion). We wished to explore
this possibility and rationalized that if cryptic sites are in-
volved in assembly, then some antibodies that inhibit as-
sembly may do so by binding to and blocking these sites.
The L8 mAb binds to a site within the adjacent I
 
9
 
 and III
 
1
 
modules in FN, and L8 blocks FN assembly into matrix
(10, 11). The staining properties of L8 were explored on
FN matrix assembled by Swiss 3T3 cells using exogenous
human plasma FN under conditions where cell contractil-
ity was modulated by the presence or absence of C3 trans-
ferase (Fig. 8). Cells grown to 50–80% confluence in the
presence of exogenous human FN were changed to serum-
free medium, with or without C3. After 24 h, cells were
stained for FN using double labeling with both polyclonal
and mAbs (Fig. 8). (It should be noted that under these
subconfluent conditions, the Swiss 3T3 cells did not be-
come quiescent when cultured in the absence of serum for
24 h, as judged by the presence of stress fibers.) In the ab-
sence of C3, L8 stained a fibrillar FN matrix indistinguish-
able from that revealed by double labeling with a poly-
clonal anti-FN antibody (Fig. 8, 
 
A
 
 and 
 
B
 
). However,
Figure 5. Binding of fibronectin and the 70-kD
fibronectin fragment to Swiss 3T3 cells is blocked
by inhibitors of Rho and contractility. (A) Time
course of fibronectin binding to cells in the pres-
ence or absence of LPA. Starved (s) or LPA-
treated (n) cell monolayers were incubated with
125I-FN for increasing lengths of time. (B) Effects
of inhibitors of Rho and contractility on the
binding of FN (black bars) or the 70-kD FN frag-
ment (open bars) to cells, and on the incorpora-
tion of FN into the DOC-insoluble matrix
(shaded bars). Serum-free (SF) and LPA-stimulated (LPA) cells without inhibitors or pretreated
with and maintained in the presence of C3, H7, or BDM were incubated for 2 h with 125I-FN or
125I-labeled 70-kD FN fragment. The amount of 125I-FN incorporated into DOC-insoluble matrix
was determined as described in Materials and Methods, after incubating cells with 125I-FN for 22 h
with or without inhibitors. Samples were assayed in duplicate and standard errors are indicated.
(C) Reversibility of inhibition of FN binding to cells by contractility inhibitors BDM and H7.
BDM- or H7-treated cells were allowed to recover in regular serum-containing medium for 2 h be-
fore a 30-min incubation with 125I-FN. Each point in A, B, and C represents the average of dupli-
cate determinations. Nonspecific binding in the presence of unlabeled FN (400 mg/ml) or 70-kD
FN fragment (100 mg/ml) was subtracted. 
Figure 6. Binding of the 70-kD FN fragment to R-MCF10A cells
and incorporation of FN into the cross-linked matrix is decreased
by inhibitors of contractility. R-MCF10A cells were untreated
(Control) or treated for 2 h with 20 mM BDM, or 25 mM ML-7,
followed by incubation with 125I-labeled 70-kD FN fragment for
another 1.5 h (black bars). Alternatively, R-MCF10A cells were
incubated with 125I-FN for 18 h in low serum, either in the ab-
sence (Control) or presence of 2.4 mM BDM or 2.5 mM ML-7. In-
corporation of FN into the DOC-insoluble fraction is shown
(white bars). Results were from three independent experiments.
Figure 7. Effects of C3 and
inhibitors of contractility on
the activation state of b1 in-
tegrins. b1 integrin activation
was measured by the binding
of  125I-labeled 12G10 anti-
body to R-MCF10A mono-
layers in the absence of any
agents (control) or in the
presence of 20 mM BDM,
150  mM H7, 25 mM ML-7, or
25 mg/ml C3. Cells were ex-
posed to these agents for 2 h, except for C3 which was included in
the culture medium for 2 d. Full activation of b1 integrins was
achieved by treating control cells with 100 mM MnCl2. Experi-
ments were performed in triplicate. Results are represented as
the percentage of the value obtained with MnCl2. 
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compared with the staining obtained with the polyclonal
antibody, the staining by L8 was decreased when cells
were incubated with C3 (Fig. 8, C and D). Similarly, the
staining with L8, but not the polyclonal antibody, was also
diminished in cultures treated with inhibitors of contractil-
ity such as H7 (data not shown). Other mAbs, such as
C6F10, did not show this differential staining pattern (Fig.
8, E–H), indicating that this was not a general characteris-
tic of mAbs directed against FN.
Radiolabeled antibodies were used to quantitate the ef-
fects of C3 on the binding of L8 and C6F10 to FN matrices.
Parallel cultures were incubated with either 125I-labeled L8
or C6F10 and the ratio of bound counts determined (Fig. 9).
The ratio of L8 to C6F10 binding to cultures decreased by
approximately threefold when cultures were treated with C3.
Mechanical Stretching of FN Exposes Binding Sites and 
Promotes Self-Assembly
We wished to determine whether mechanically stretching
FN in the absence of cells exposed sites for self-assembly
and, in particular, the L8 epitope. To stretch FN we took
advantage of “Bioflex” tissue culture plates that were de-
signed to allow cultured cells to be exposed to cyclic
stretch (4). FN (10 mg/ml) was coupled covalently to the
rubber surface of these plates, generating a FN density of
z3.5 ng/mm2. Using a molecular mass for the FN dimer of
500 kD, we calculated that this corresponds to z4 3 103
molecules/mm2. If all the molecules were spread out flat,
based on the calculations of Lightner and Erickson (38),
this should more than saturate the surface. Because in-
creased binding of FN to the surface was obtained by ex-
tending the coupling reaction, we conclude that some of
the molecules were not spread out flat and must have ex-
tended up from the surface. 
The binding of 125I-FN and 125I-labeled 70-kD FN frag-
ment to the FN-coated surfaces was measured with and
without stretching for 1 h (Fig. 10 A; Table I). In both
cases, specific binding to unstretched FN was low and
close to the value for nonspecific binding, defined as the
amount bound in the presence of 1 mg/ml of unlabeled
ligand. Specific binding was significantly increased when
Figure 8. Inhibition of Rho decreases selectively
the staining of FN matrices by the L8 mAb. Swiss
3T3 cells were grown to 50–80% subconfluence
in media containing serum supplemented with 80
mg/ml human plasma FN. The medium was re-
placed with serum-free media with or without 25
mg/ml C3 and the cells cultured for a further 24 h.
The FN matrix was visualized by double-labeling
with polyclonal antibodies to FN (A, C, E, and
G) or with mAbs, L8 (B and D) and C6F10 (F
and H). Untreated cells are shown in A, B, E,
and F. Cells treated with C3 are shown in C, D,
G, and H. Note that the mAbs give an essentially
identical staining pattern to the polyclonal anti-
body with the exception of reduced L8 staining
in the presence of C3. Arrows in C and D indi-
cate regions of differential staining between the
polyclonal antibody and L8. Bar, 20 mm.Zhong et al. Rho, Contractility and Fibronectin Matrix Assembly 547
the surfaces were stretched (30–35% in a linear dimen-
sion) (Fig. 10 A; Table I).
We also examined the binding of 125I-labeled L8 and
C6F10 mAbs to FN in stretched and unstretched condi-
tions (Fig. 10 B; Table I). The binding of 125I-L8 to un-
stretched FN was low and not much above the value for
nonspecific binding, consistent with the L8 epitope being
inaccessible in most unstretched FN molecules. In con-
trast, the binding of C6F10 to unstretched FN was rela-
tively high and considerably above the value for nonspe-
cific binding. A slight increase was observed in binding of
C6F10 to stretched FN. This was not statistically signifi-
cant, but was observed on multiple occasions, possibly re-
flecting an increased accessibility of the antibody to FN
molecules that had been sterically blocked by other over-
lapping FN molecules on the unstretched surface. In com-
parison, the binding of L8 to stretched FN was signifi-
cantly increased, indicating exposure of the epitope upon
stretching (Fig. 10 B; Table I).
Discussion
In this work we have demonstrated that Rho-mediated
contractility stimulates the assembly of a fibrillar FN ma-
trix. In addition, we have shown that tension applied di-
rectly to FN in the absence of cells generates binding sites
for additional FN molecules and, in particular, for the 70-kD
NH2-terminal domain of FN, which is critical for matrix as-
sembly (42). Our studies were motivated by an interest in
the low molecular weight G protein Rho, and by the ear-
lier observations that LPA stimulates FN matrix assembly
(9, 71). Because Rho is one of several downstream effec-
tors of LPA (43), and because the assembly of FN corre-
lates with the development of stress fibers (31) that are
regulated by Rho activity (57), it seemed likely to us that
Rho may regulate FN matrix assembly. We have shown
that this is indeed the case, blocking matrix assembly by a
variety of inhibitors of contractility as well as by inhibiting
Rho itself using the C3 transferase. Similar results have
been reported recently by Mosher’s group (70) while this
work was under review.
The assembly of FN into a fibrillar matrix is a complex
process involving multiple steps. Previous work has dem-
onstrated a role for integrin activation in this process and
several studies have suggested that integrin activation may
be regulated by Rho (37, 45, 64). While investigating the
effect of cell contractility on FN matrix assembly, we con-
sidered the possibility that agents that affect contractility
might also be affecting integrin activation. To address this
question, we used a cell type in which we could assay the
state of b1 integrin activation with a mAb that recognizes
an activation-dependent epitope. Treatment of cells with
inhibitors of contractility at concentrations that blocked
matrix assembly had no effect on integrin activation. How-
ever, with C3 a slight decrease in integrin activation was
observed. Although Rho may exert some effect on matrix
assembly by affecting the activation state of integrins, the
predominant effect would appear to be via Rho-stimu-
lated contractility. Consistent with this interpretation are
the results with the FN 70-kD fragment. This NH2-termi-
nal domain of FN does not interact with integrins, but its
binding to cells is stimulated by LPA (71). Significantly,
this interaction is decreased both by inhibiting Rho and by
inhibiting contractility (see reference 70 in addition to
these results). We conclude that, in cells already express-
ing activated integrins, Rho-stimulated contractility is crit-
ical for the assembly of a FN matrix. Our findings are con-
sistent with the observations of Halliday and Tomasek,
who showed that cells in a collagen gel assemble a FN ma-
trix if they exert tension on the gel, but fail to assemble FN
in gels without tension (26).
Figure 9. Inhibition of bind-
ing of L8 mAb to FN matrix
by the Rho inhibitor C3. Par-
allel dishes of Swiss 3T3 cells
supplemented with 80 mg/ml
of human plasma FN were
changed to serum-free media
with or without C3 for 24 h.
Binding of 125I-labeled mAb
L8 or C6F10 was determined.
The level of nonspecific
binding was calculated by
competition with excess un-
labeled antibody and these
values were used to calculate
the levels of specific binding.
The ratio of specific binding
of L8 to C6F10 was deter-
mined for untreated cells (Control) and cells treated with C3
(C3). Three independent experiments were performed.
Figure 10. Mechanical stretching of purified fibronectin stimu-
lates binding of fibronectin, the 70-kD fibronectin fragment and
the L8 mAb. FN covalently coupled to rubber surfaces was left
unstretched or stretched as described in the Materials and Meth-
ods. The surfaces were incubated with 125I-labeled FN, 70-kD FN
fragment or mAbs C6F10 and L8. Specific binding was calculated
as described in the Materials and Methods. Open columns repre-
sent the binding to unstretched surfaces, shaded columns repre-
sent the binding to stretched surfaces. Each column represents
the mean of six measurements (FN and 70-kD FN fragment bind-
ing) or triplicate measurements (C6F10 and L8). Error bars indi-
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We can conceive of several ways by which tension/con-
tractility could contribute to FN matrix assembly. One
possible mechanism derives from previous work demon-
strating that Rho induces integrin clustering (15, 30). In
the case of integrins bound to FN, tension-induced cluster-
ing would juxtapose FN molecules possibly in a conforma-
tion favorable to promote self-assembly. The clustering re-
sulting from tension would also be expected to aggregate
small fibrils into larger fibrils typical of a mature ECM. Al-
though clustering integrins would effectively concentrate FN
molecules, this mechanism does not account for the ob-
served increase in the number of binding sites for the 70-kD
NH2-terminal fragment of FN that are induced by LPA (71).
An alternative mechanism is that tension applied di-
rectly to FN exposes self-assembly sites to which addi-
tional FN molecules may bind. Our results with FN
stretched mechanically support this hypothesis. Tension
on FN could expose self-assembly sites either by unfolding
a large region of FN that is looped back on itself, or by
partially unfolding FN type III domains. The existence of a
loop structure in native FN is controversial but favored by
some investigators. Evidence exists for several intramolec-
ular associations, such as the binding of the I1–5 modules in
the NH2-terminal 70-kD domain to the III1 module (1, 12,
46). Such an interaction within a single molecule would
generate a loop. Schwarzbauer and colleagues have found
that deleting the first seven type III modules accelerates
the incorporation of FN into the insoluble FN matrix (59,
60). Accelerated incorporation suggests that the deleted
construct has removed some constraint on assembly. This
is consistent with a loop structure for the native FN, which
has to be unfolded for incorporation of native FN into the
assembling matrix. Morla and Ruoslahti demonstrated
that a peptide from the III1 module interacted with intact
FN and promoted assembly into an insoluble matrix in the
absence of cells (47). This is also consistent with opening
of a loop by the III1 peptide with consequent exposure of
masked binding sites. 
The FN constructs lacking the first seven type III mod-
ules, although they incorporate more rapidly than native
FN, take much longer to generate a fibrillar matrix (60).
However, the incorporation of these truncated constructs
into a matrix implies that the I1–5 modules involved in ma-
trix assembly must be binding to something on the cell sur-
face other than the III1 domain. Support for this has been
provided by Sottile and Mosher, who identified two dis-
tinct binding sites within I1–5 (63). Modules I4,5 were shown
to interact with III1, but modules I1–3 inhibited binding of
the NH2-terminal 70-kD fragment of FN to cells, indicat-
ing that these modules bind to another as yet unidentified
site important in assembly. Whether this is elsewhere on
FN or a distinct surface molecule has not been deter-
mined. 
A second way by which tension may expose cryptic
binding sites in FN is by causing some unfolding of FN
type III modules. This idea was first suggested and consid-
ered theoretically by Erickson (19), both in the context of
FN as well as the muscle structural protein titin, which
contains many FN type III modules and that is subject to
considerable stretching. The energy to unfold a type III
module was calculated to be surprisingly small and in the
same range as the force generated by one or a few myosin
motors interacting with actin (19). Evidence that there are
cryptic binding sites within FN type III modules has been
provided by McKeown-Longo’s group (28, 29). Cryptic
sites have been found both within the III1 module for
binding the NH2-terminal 70-kD FN fragment (28), and
within the III10 module for binding the III1 module (29).
Similarly, Ingham and coworkers have identified addi-
tional cryptic sites within III7 and III15 for III1 (33). The
exposure of these or other sites involved in FN assembly
by tension has been suggested previously (13, 28, 67), al-
though direct evidence for this has been missing. Intrigued
by the possibility that tension may expose cryptic sites in
FN, we looked for a reagent that might reveal such a site.
The L8 mAb, which binds to I9/III1 and blocks matrix as-
sembly (11, 12), appears to be such a reagent. Under nor-
mal conditions of culture, this antibody labels FN matri-
ces. However, when cell contractility is inhibited by C3,
the binding of L8 to the FN matrix is reduced, consistent
with an epitope that is exposed by tension exerted on the
FN molecule. 
We wanted to examine this possibility directly by stretch-
ing FN in the absence of cells. In addition, it seemed to us
that if tension exposes self-assembly sites within FN, it
should be possible to detect these in isolated FN molecules
being stretched mechanically. We explored several poten-
tial ways of applying tension to FN before settling on a sys-
tem that allowed covalent coupling of FN to rubber sur-
faces that could be stretched easily. We found that
stretched FN revealed increased binding of intact FN and
the 70-kD NH2-terminal FN fragment. Moreover, com-
pared with a control mAb, L8 showed elevated binding to
the stretched FN. These findings lead us to conclude that
stretched FN does expose cryptic binding sites and can nu-
cleate FN assembly.
It is relevant that FN matrix assembly is often observed
at sites of tension, such as beneath cells (32) and, in partic-
ular, at focal adhesions, where tension is transmitted to the
underlying substratum. A striking example of this is seen
Table I. Binding of FN, 70-kD FN Fragment, L8, and C6F10 
mAbs to Unstretched and Stretched FN
Specific
binding
Nonspecific
binding
Ratio stretched/
unstretched p value
cpm cpm t test
FN, unstretched 498 (6 103) 6,947 (6 499)
FN, stretched 3,688 (6 735) 6,948 (6 298) 7.4 0.01
70 kD,
unstretched
1,447 (6 283) 4,469 (6 589)
70 kD, stretched 4,099 (6 588) 5,464 (6 334) 2.8 0.005
L8, unstretched 2,052 (6 839) 7,327 (6 92)
L8, stretched 15,497 (6 897) 10,905 (6 508) 7.6 0.0004
C6F10,
unstretched
23,941 (6 2,255) 3,239 (6 72)
C6F10, stretched 27,382 (6 2,457) 5,049 (6 241) 1.1 0.36
Values for binding of 125I-labeled ligands and antibodies to unstretched and stretched
FN are shown. Specific binding is the binding obtained after subtraction of the non-
specific binding. Nonspecific binding was the value obtained in the presence of 1 mg/
ml of unlabeled ligand (FN or 70-kD FN fragment) or 0.5 mg/ml of unlabeled anti-
body. For FN and 70-kD FN fragment, the means of six measurements are shown; for
the antibodies, the means of triplicate measurements are shown. The standard errors of
the means are indicated in parentheses. The ratio of counts bound to the stretched ver-
sus the unstretched FN (i.e., the fold increase in binding in response to stretching) is
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when cells are plated on fluorescent FN adsorbed to a
glass coverslip (3, 25). In this situation, matrix assembly
occurs as cells exert tension on the underlying FN and pull
it off the coverslip. Similarly, FN fibrils are frequently de-
tected stretching between adjacent cells in an alignment
that suggests tension. For tension to be exerted on a FN
dimer, forces have to be applied either in opposing direc-
tions to two sites in the dimer (an unlikely situation for a
single cell), or force has to be applied to one site in a dimer
that is tethered in some way to a relatively immobile struc-
ture. Tethering of FN to tissue culture surfaces is a fre-
quent occurrence because FN adsorbs well to glass and
plastic. However, tethering may also occur to adjacent cells
or to other ECM components. 
Any model for FN assembly into fibrils must satisfy mul-
tiple experimental observations, including the need for a
functional actin cytoskeleton and the need for tension
demonstrated here and previously (26, 70). Several critical
sites in FN have been identified. The cell-binding site
(module III10), which interacts with integrins (particularly
a5b1) and the adjacent synergy site (module III9), are
both required as evidenced by the inhibition of assembly
by antibodies that bind to these regions (20, 41, 54) and by
the need for integrin activation (67). The 70-kD NH2-ter-
minal region of FN (including the I1–5 modules) is also re-
quired (42). This region of FN binds to cells, but not
through integrins. Cell surface receptors for this domain
have been elusive, although several candidates have been
identified (5, 39, 44, 69). However, this region of FN also
associates with the III1 module within FN (1, 28, 55) and
has been implicated in generating the loop structure at the
NH2 terminus of FN, discussed above. Antibodies against
the III1 module block matrix assembly (11, 12). Models of
assembly must account for the observation that deleting
the first seven type III modules accelerates incorporation
of FN into the DOC-insoluble matrix (i.e,. the cross-linked
polymer) (59, 60). These findings indicate that other bind-
ing sites for the 70-kD region of FN exist beside the III1
module and evidence for such sites has been obtained (63). 
Combining these various observations with the require-
ment for cell contractility, we favor a model that is illus-
trated in Fig. 11. We envisage soluble FN protomers being
folded in their NH2-terminal regions, so that the I4,5 mod-
ules interact with the III1 module (63). The incoming FN
assembles onto FN that is under tension, with the tension
exposing multiple cryptic binding sites within FN type III
modules (three are indicated in Fig. 11). The transmission
of tension from the cytoskeleton to FN accounts for the
need both for an intact cytoskeleton as well as for func-
tional (activated) integrins in FN fibril assembly. One of
the exposed binding sites is the L8 epitope (within I9/III1).
In Fig. 11, the domain on the incoming FN interacting with
III1 is designated “X,” because its identity is uncertain.
However, several modules have been found to bind III1 in
vitro, including I4,5, III10, III7, and III15 (1, 28, 29, 33, 63).
Further work will be required to determine which interac-
tions are inhibited by L8. A second site that appears to be
exposed by tension is within III10. This module has a con-
formation-dependent binding site for III1 (29). Interest-
ingly, isolated III1 domains target to focal adhesions when
cells are plated on cell-binding fragments of FN, some of
which may be as small as the combined III10 module and
the adjacent synergy site III9 (29). This is consistent with
the incoming III1 module binding to stretched III10 mod-
ules within focal adhesions. The postulated loop structure
in the incoming FN may be opened by the interaction of
the I1–3 modules with a COOH-terminal, stretched type III
module marked “Y” in Fig. 11. Alternatively, the interac-
tion of the incoming FN III1 module with the stretched
III10 may lower the affinity of III1 for the I4,5 modules in
the 70-kD domain, thereby opening the loop. This is simi-
lar to the model proposed by Sechler and coworkers, who
suggested that integrin binding to III10 affects the interac-
tions of III1 with the NH2 terminus of FN causing the loop
to open (60). Here we suggest that the conformational
change induced by integrin binding may be due to the ten-
sion transmitted to FN rather than the binding itself, al-
though binding and tension may both contribute. Upon
opening of the NH2-terminal loop, the I1–3 modules bind to
the type III module marked “Y” in Fig. 11. This postulated
site should be critical in binding the 70-kD FN fragment to
cells (the “matrix assembly site”) and is also regulated by
tension, as evidenced by its exposure by LPA and its inhi-
bition by inhibitors of contractility (62, 70, 71; and this pa-
Figure 11. A model for tension-induced fibronectin assembly.
(A) shows part of a soluble FN molecule that is going to interact
with a tethered FN molecule under tension (for example, span-
ning between a cell and the substratum). (B) shows the interact-
ing pair. The incoming FN in (A) has an intramolecular loop re-
sulting from the III1 module binding to the I4,5 modules. The
tension stretches and opens up some FN type III modules (three
are shown) exposing cryptic binding sites for domains on the in-
coming FN molecule. One of the tension-exposed binding sites is
in III1 and corresponds to the L8 epitope. This is involved in
binding a domain in the incoming FN, marked “X” in the dia-
gram. Another stretched domain is the III10 module, which ex-
poses a site that binds the III1 module of the incoming FN. A
third site is postulated in another type III module marked “Y.”
We predict that this site will bind the I1–3 modules of the incom-
ing FN. The binding of III10 to III1 may decrease the affinity of
III1 for I4,5 and so trigger opening of the loop. Alternatively, the
stretched III–Y module may exhibit a higher affinity for the I1–3
modules than the affinity of III1 for I4,5. This would also favor
opening of the NH2-terminal loop. Because only one of the pair
of interacting FN molecules is stretched, misalignment of the
anti-parallel interacting molecules would be expected. Whether
this is corrected with maturation of the fibril remains to be deter-
mined.The Journal of Cell Biology, Volume 141, 1998 550
per). In future work, it will be important to look for this
tension-regulated binding site, which we predict will be in
a type III module COOH-terminal to III10. 
Recent work has indicated that the 70-kD NH2-terminal
domain can be cross-linked to very high molecular mass
complexes on the surfaces of cells (69). These have also
been postulated to be opened by tension to expose cryptic
70-kD binding sites (70). Our data does not address the
relative contribution of such sites to matrix assembly.
However, our observations that purified, stretched FN
binds the NH2-terminal 70-kD fragment as well as other
FN molecules indicates that tension on FN alone may be
sufficient to nucleate FN polymerization.
With ECM proteins like FN, it is important that assem-
bly be tightly regulated so that it does not occur at inap-
propriate locations or times. One way to prevent sponta-
neous assembly is to have the self-assembly sites involved
in polymerization cryptic within the molecule, such that
they are only unmasked in response to physiological stim-
uli. Tension is a physiologically relevant signal and it is
noteworthy that the generation of tension and FN matrix
assembly are often coupled together. One example is the
response to wounds, a situation where tension generated
by cells and tissues contributes to wound closure and tis-
sue remodelling. Our results suggest that cell-generated
tension may be an important stimulus to the assembly and
deposition of ECM that occurs during the wound repair
process (66).
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